This document summarizes information about a biopharmaceutical company and its stroke recovery treatment called NeuroAiDTM. The company was incorporated in 2003 by renowned scientists and businessmen to focus on safety, quality, and clinical data. NeuroAiDTM aids in faster and fuller neurological recovery from stroke. It is effective in both early and late stages when taken as an add-on treatment to rehabilitation. Several publications and clinical trials demonstrate NeuroAiDTM's efficacy in improving motor function, speech, vision and other cognitive abilities in stroke patients. The company is pursuing global expansion and clinical trials of NeuroAiDTM through affiliates and a network of leading clinicians.

1. Start Recovering Now
Enhances Stroke Recovery and Supports
Neurological Functions

2. Stroke has a devastating impact on million of lives
Stroke is the leading cause of adult disability worldwide
• A stroke occurs every 2 seconds
• 15 Million strokes per year (2/3 only partial recovery)
Patients are left without a treatment
• Neuroprotective agents have not (yet) delivered their promise
• Hyper acute intravenous thrombolysis available only to a minority of
patients
• Lack of pharmacological modalities to support post stroke recovery
• Patients grow desperate and frustrated
Interest to look at new sources of therapeutics

3. • Biopharmaceutical company incorporated in 2003
• By a group of renown scientists from east and west and businessmen.
• Focus on safety, quality and clinical data
• Offices in Singapore and Paris
• Important involvement & initiative of academic/key opinion leaders & clinicians.
SCIENTIFIC ADVISORY BOARD, MEDICAL EXPERTS AND INVESTIGATORS
TCM understanding, Biology and EBM expertise,
Acad. Shi Xuemin Georges Charpak
Etienne Beaulieu
Former President, Tianjin First Teaching Nobel Laureate
Hospital of TCM
French Academy
of Sciences
Michel Lazdunski Prof. Zhao Guo Ping Acad Han Ji Sheng
Director Pharmacology, Shanghai Genome Beijing
CNRS Center Neuroscience Inst.
MG Bousser
Pr Geoffrey Donnan Dr Christopher CHEN
Advisor on Stroke and
National Stroke Singapore
Migraine(France)
Institute, University of National University of
Melbourne, Australia Singapore

4. Awards recognitions
“Moleac introduced in the “Moleac receives the Frost &
market NeuroAiD™, the first Sullivan Asia Pacific Excellence in
treatment that brings faster and Healthcare Award for the success
fuller recovery for stroke of its stroke treatment drug
patients...” NeuroAiD™...”

5. NeuroAiD™ treatment

6. Introduction to NeuroAiD™
• NeuroAiD™ is a post stroke recovery medicine for faster and fuller neurological
recovery
• It aids in recovering your independence and reducing neurological deficits
• Effective at early and late stage of stroke as an add-on treatment
• Strong clinical data on efficacy and safety
• 0.5 million patients in 25 countries
Details
• 3 months treatment recommended . Results usually observed within one month
• Capsule form - (can be opened and diluted in water or administrated via gastric tube)
• NeuroAiD™ should be initiated as soon as possible post stroke and it has shown to be
effective up to at least 6 months post stroke.
Aimed at long term reduction of disabilities after a stroke

7. How NeuroAiD™ improves
Clinical trials and number of case reports
demonstrated improvements in : MOTOR – Stroke publication
reports that patients on
NeuroAiD™ showed a 25%
- Motor functions, higher recovery in motor
- Speech (anomia, aphasia) deficits after one month
treatment.
- Vision (hemianopia, diplopia)
- Other cognitive.
VISION – case study in
European Neurology journal
reports several improvements
of vision disabilities, with
resolution of diplopia and
hemianopia.
SPEECH – case study in
European Neurology journal
reports several improvements
of vision disabilities, with
resolution of anomia and
aphasia.

8. Introduction to NeuroAiD™
Footage
• NeuroAiD™ commercialization is pursued through a network of affiliates
• In the European Union our subsidiaries in Paris prepare the registration
• We are pursuing exponential geographic expansion
Iran Vietnam Europe
Jordan Indonesia Eastern Europe
Lebanon Algeria CIS
Lebanon Iraq Russia USA
Philippines Thailand Mexico Middle-East
Singapore Malaysia Pakistan Argentina Korea…
2007 2008 2009 2010 2011

9. NeuroAiD™ in stroke treatment
4 - 5 hours First day 24 hours 1 week 6 months
Stroke onset
Hyper acute
therapies
such as: rTPA
Rehabilitation
Window to start the treatment with NeuroAiD™
Acute stage Late stage
NeuroAiD™ has shown efficacy in acute and late post-stroke stage.

10. Publications
Medical marketing – Publications

11. Scientific publications
• 7 recent publications summarize NeuroAiD™’s efficacy data, pharmacology data and excellent
tolerability :
– Neuropharmacology in 2010 – Pharmacology data
– Cerebrovascular Diseases in 2010 - Safety data in acute stage
– Cerebrovascular Diseases TIERS in 2009 – Pilot study
– Stroke Journal in 2009 – Efficacy trial
– European Neurology in 2008 – Case report
– Cerebrovascular Diseases in 2008 – Safety trial
– The International Journal of Stroke in 2009 – The CHIMES
protocol

12. Summary of existing clinical evidence
• Pharmacological data show neuroproliferative, neuroregenerative and
neuroprotective properties
• Patients on NeuroAiD™ had 2.4 times more chances to achieve independence
after one month of treatment
• Patients on NeuroAiD™ showed a 25% higher recovery in the motor components
• Many studies and case reports (even at late stage of stroke onset) show good
recovery in motor function, balance, visual and speech functions for patients taking
NeuroAiD™
•NeuroAiD™ does not modify hematological, hemostatic, and biochemical and
ECG parameters in normal subjects and stroke patients

13. Clinical Trials

14. Clinical trials
Clinical trials
CHIMES sites
R&D
14

15. Clinicians leading the CHIMES trial
Prof MG BOUSSER Dr Christopher CHEN
Hôpital Lariboisière National University
France Singapore
DMSB SINGAPORE PHILIPPINES
Prof. Geoffrey DONNAN 4 Centres recruiting:
National Stroke Institute – University of Santo Tomas, Jose
All 4 centres: NUH
University of Melbourne Reyes Medical Centre, Davao
SGH, TTSH, CGH
Australia Medical Center; Philippines General
Dr N.V. RAMANI,
Prof David MACHIN Dr Sherry Young, Hospital
CTERU Dr. Bernard CHAN,
Singapore Dr CHANG Hui Meng Prof Jose NAVARRO,
Dr Rajinder Singh Dr Alejandro C. BAROQUE,
Prof Christophe TZOURIO Dr Hil Gan,
Paris - France Dr Annabelle Lao
Dr Carlos I Chua (PI)
THAILAND Dr Cristina M San Jose
CTERU (academic CRO) 5 Centres
Dr Tan Say Beng Siriraj Hospital
Clinical Trials and Epidemiology Research Chiangmai University Hospital More centres in discussion in
Unit Chulalongkorn Hospital • Pakistan
King Mongkutla Hospital • Indonesia
Thammasat Hospital • Malaysia
SRI LANKA • Hong Kong
Prof Niphon Poungvarin
Dr Asita da Silva Dr Siwaporn Chankrachang
University of Kelaniya Dr Nijasri Suwanwela,
Dr Samart Nidhinandana
Dr Sombat Muengtaweepongsa
Chimes provides an important platform
Access to leading clinicians / further data on NeuroAiD™ when started within 72h after stroke onset

16. Thank You
Find out more
www.neuroaid.com